A composition for predicting irinotecan chemotherapy toxicity biomarkers
A technique for irinotecan, chemotherapy toxicity, applied in the field of predicting biomarkers
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0103] The composition and exact content of the biomarker combination used to predict irinotecan delayed diarrhea are shown in Table 2:
[0104] Table 2 Differential metabolites predicting delayed diarrhea sensitive vs non-sensitive
[0105]
Embodiment 2
[0107] The combination of biomarkers used to predict irinotecan myelosuppression, its composition and accurate content are shown in Table 3: Table 3 predicts the differential metabolites of myelosuppression-sensitive vs non-sensitive
[0108]
[0109]
Embodiment 3
[0111] A composition predictive of sensitivity to irinotecan chemotherapy toxicity, the ratio of each component being:
[0112] Glycocholic acid: 2.04~2.86;
[0113] Phenylalanine: 55.23~69.07;
[0114] Cholic acid: 24.44~34.12;
[0115] Deoxycholic acid: 1.72~2.52;
[0116] And, or, unit: any one of μmol, μmol / L.
[0117] The use of the composition is: take the composition as a reference substance, detect the content of the above four substances in the sample, so as to predict the sensitivity of the organism to the chemotherapy toxicity of irinotecan.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More 


